High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy

British Journal of Cancer

Volumn 94, Issue 9, 2006, Pages 1226-1230

  De Jonge, M E ^a   Huitema, A D R ^a   Beijnen, J H ^a,b   Rodenhuis, S ^b  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Bioactivation; Correlation; Cyclophosphamide; Exposure; Veno occlusive disease

Indexed keywords

4 HYDROXYCYCLOPHOSPHAMIDE; CARBOPLATIN; CYCLOPHOSPHAMIDE; PHOSPHORAMIDE MUSTARD; THIOTEPA;

AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; DRUG ACTIVATION; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG METABOLISM; GERM CELL TUMOR; HUMAN; LIVER VENOOCCLUSIVE DISEASE; MAJOR CLINICAL STUDY; OVARY CANCER; PREDICTION; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; BREAST NEOPLASMS; CARBOPLATIN; CYCLOPHOSPHAMIDE; FEMALE; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; INFUSIONS, INTRAVENOUS; NEOPLASMS, GERM CELL AND EMBRYONAL; OVARIAN NEOPLASMS; THIOTEPA;

EID: 33646504460     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603097     Document Type: Article

References (29)

1. Ayash LJ, Hunt M, Antman K, Nadler L, Wheeler C, Takvorian T, Elias A, Antin JH, Greenough T, Eder JP (1990) Hepatic venoocclusive disease in autologous bone marrow transplantation of solid tumors and lymphomas. J Clin Oncol 8: 1699-1706
2. Ayash LJ, Wright JE, Tretyakov O, Gonin R, Elias A, Wheeler C, Eder JP, Rosowsky A, Antman K, Frei III E (1992) Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response. J Clin Oncol 10: 995-1000
3. Beal SL, Sheiner LB (1998) NONMEM User's Guides, NONMEM Project Group. San Francisco: University of California at San Francisco
4. De Jonge ME, Huitema ADR, Rodenhuis S, Beijnen JH (2004) Integrated population pharmacokinetic model of both cyclophosphamide and thiotepa suggesting a mutual drug-drug interaction. J Pharmacokin Pharmacodyn 31: 135-156
5. De Jonge ME, Huitema ADR, Rodenhuis S, Beijnen JH (2005) Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 44: 1135-1164
6. DeLeve LD (1996) Cellular target of cyclophosphamide toxicity in the murine liver: Role of glutathione and site of metabolic activation. Hepatology 24: 830-837
7. Fraiser LH, Kanekal S, Kehrer JP (1991) Cyclophosphamide toxicity. Characterizing and avoiding the problem. Drugs 42: 781-795
8. Hassan M, Ljungman P, Ringden O, Hassan Z, Oberg G, Nilsson C, Bekassy A, Bielenstein M, Abdel-Rehim M, Georen S, Astner L (2000) The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity. Bone Marrow Transplant 25: 915-924
9. Honjo I, Suou T, Hirayama C (1988) Hepatotoxicity of cyclophosphamide in man: pharmacokinetic analysis. Res Commun Chem Pathol Pharmacol 61: 149-165
10. Huitema AD, Mathôt RAA, Tibben MM, Rodenhuis S, Beijnen JH (2001) A mechanism-based pharmacokinetic model for the cytochrome P450 drug-drug interaction between cyclophosphamide and thioTEPA and the autoinduction of cyclophosphamide. J Pharmacokinet Pharmacodyn 28: 211-230
11. Huitema AD, Spaander M, Mathôt RAA, Tibben MM, Holtkamp MJ, Beijnen JH, Rodenhuis S (2002) Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thioTEPA and carboplatin. Ann Oncol 13: 374-384
12. Huitema AD, Tibben MM, Kerbusch T, Zwikker JW, Rodenhuis S, Beijnen JH (1998) Simultaneous determination of N,N′,N″- triethylenethiophosphoramide, cyclophosphamide and some of their metabolites in plasma using capillary gas chromatography. J Chromatogr B, Biomed Sci Appl 716: 177-186
13. Huitema ADR, Tibben MM, Kerbusch T, Kettenes-van den Bosch JJ, Rodenhuis S, Beijnen JH (2000a) High performance liquid chromatographic determination of the stabilized cyclophosphamide metabolite 4-hydroxycyclophosphamide in plasma and red blood cells. J Liq Chrom Rel Technol 23: 1725-1744
14. Huitema ADR, Tibben MM, Kerbusch T, Kettenes-van den Bosch JJ, Rodenhuis S, Beijnen JH (2000b) Simple and selective determination of the active cyclophosphamide metabolite phosphoramide mustard in human plasma using high-performance liquid chromatography. J Chromatogr B 745: 345-355
15. McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M, Hardin BJ, Shulman HM, Clift RA (1993) Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients. Ann Intern Med 118: 255-267
16. McDonald GB, Slattery JT, Bouvier ME, Ren S, Batchelder AL, Kalhorn TF, Schoch HG, Anasetti C, Gooley T (2003) Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood 101: 2043-2048
17. Nevill TJ, Barnett MJ, Klingemann HG, Reece DE, Shepherd JD, Phillips GL (1991) Regimen-related toxicity of a busulphan-cyclophosphamide conditioning regimen in 70 patients undergoing allogeneic bone marrow transplantation. J Clin Oncol 9: 1224-1232
18. Nieto Y, Xu X, Cagnoni PJ, Matthes S, Shpall EJ, Bearman SI, Murphy J, Jones RB (1999) Nonpredictable pharmacokinetic behaviour of high-dose cyclophosphamide in combination with cisplatin and 1,3-bis(2-chloroethyl)-1- nitrosurea. Clin Cancer Res 5: 747-751
19. Petros WP, Broadwater G, Berry D, Jones RB, Vredenburgh JJ, Gilbert CJ, Gibbs JP, Colvin OM, Peters WP (2002) Association of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics with survival, toxicity, and dosing weight in patients with primary breast cancer. Clin Cancer Res 8: 698-705
20. Ren S, Slattery JT (1999) Inhibition of carboxyethylphosphoramide mustard formation from 4-hydroxycyclophosphamide by carmustine. AAPS Pharm Sci 1: E14
21. Rodenhuis S, Bontenbal M, Beex LV, Wagstaff J, Richel DJ, Nooij MA, Voest EE, Hupperets P, van Tinteren H, Peterse HL, TenVergert EM, de Vries EG, Netherlands Working Party on Autologous Transplantation in Solid Tumors (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med 349: 7-16
22. Rodenhuis S, de Wit R, de Mulder PHM, Keizer HJ, Sleijfer DT, Lalisang RI, Bakker PJ, Mandjes I, Kooi M, de Vries EG (1999) A multi-center prospective phase II study of high-dose chemotherapy in germ-cell cancer patients relapsing from complete remission. Ann Oncol 10: 1467-1473
23. Rodenhuis S, Richel DJ, van der Wall E, Schornagel JH, Baars JW, Koning CC, Peterse JL, Borger JH, Nooijen WJ, Bakx R, Dalesio O, Rutgers E (1998) Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet 352: 515-521
24. Rodenhuis S, Westermann A, Holtkamp MJ, Nooijen WJ, Baars JW, van der Wall E, Slaper-Cortenbach IC, Schornagel JH (1996) Feasibility of multiple courses of high-dose cyclophosphamide, thiotepa, and carboplatin for breast cancer or germ cell cancer. J Clin Oncol 14: 1473-1483
25. Schrama JG, Baars JW, Holtkamp MJ, Schornagel JH, Beijnen JH, Rodenhuis S (2001) Phase II study of a multi-course high-dose chemotherapy regimen incorporating cyclophosphamide, thiotepa, and carboplatin in stage IV breast cancer. Bone Marrow Transplant 28: 173-180
26. Scott TR, Kirsch RE (1988) Inhibition of rat liver glutathione S-transferase isoenzymes by acrolein. Biochem Int 16: 439-442
27. Shulman HM, McDonald GB, Matthews D, Doney KC, Kopecky KJ, Gauvreau JM, Thomas ED (1980) An analysis of hepatic veno-occlusive disease and centrilobular hepatic degeneration following bone marrow transplantation. Gastroenterology 79: 1178-1191
28. Van Warmerdam LJC, Van Tellingen O, Maes RAA, Beijnen JH (1995) Validated method for the determination of carboplatin in biological fluids by Zeeman atomic absorption spectrometry. Fresenius J Anal Chem 351: 1820-1824
29. Yule SM, Price L, McMahon AD, Pearson AD, Boddy AV (2004) Cyclophosphamide metabolism in children with non-Hodgkin's lymphoma. Clin Cancer Res 10: 455-460